Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Sep;56(3):295–299. doi: 10.1038/bjc.1987.192

Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.

I O Ellis 1, J Bell 1, J M Todd 1, M Williams 1, C Dowle 1, A R Robins 1, C W Elston 1, R W Blamey 1, R W Baldwin 1
PMCID: PMC2002198  PMID: 3663477

Abstract

Immunocytochemical staining with monoclonal antibody NCRC 11 of formalin fixed paraffin embedded tumour tissue has been studied in 444 cases of primary breast cancer with a minimum follow period of 6 years. The relationship between extent of staining, assessed on a four point scale, and patient survival has been confirmed. There are significant relationships between staining and both histological grade and oestrogen receptor status. No association has been shown between staining and lymph node stage or tumour size. Simplification of staining assessment by modification to two staining groups still allows significant separation of patients into prognostic groups and incorporation into an existing prognostic index.

Full text

PDF

Images in this article

296Figure 1
on p.296

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angus B., Napier J., Purvis J., Ellis I. O., Hawkins R. A., Carpenter F., Horne C. H. Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11. J Pathol. 1986 Aug;149(4):301–306. doi: 10.1002/path.1711490406. [DOI] [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berry N., Jones D. B., Smallwood J., Taylor I., Kirkham N., Taylor-Papadimitriou J. The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer. 1985 Feb;51(2):179–186. doi: 10.1038/bjc.1985.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ellis I. O., Hinton C. P., MacNay J., Elston C. W., Robins A., Owainati A. A., Blamey R. W., Baldwin R. W., Ferry B. Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) 1985 Mar 23;290(6472):881–883. doi: 10.1136/bmj.290.6472.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ellis I. O., Robins R. A., Elston C. W., Blamey R. W., Ferry B., Baldwin R. W. A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology. 1984 May;8(3):501–516. doi: 10.1111/j.1365-2559.1984.tb02360.x. [DOI] [PubMed] [Google Scholar]
  6. Elston C. W. The assessment of histological differentiation in breast cancer. Aust N Z J Surg. 1984 Feb;54(1):11–15. doi: 10.1111/j.1445-2197.1984.tb06677.x. [DOI] [PubMed] [Google Scholar]
  7. Haybittle J. L., Blamey R. W., Elston C. W., Johnson J., Doyle P. J., Campbell F. C., Nicholson R. I., Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982 Mar;45(3):361–366. doi: 10.1038/bjc.1982.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hilkens J., Kroezen V., Bonfrer J. M., De Jong-Bakker M., Bruning P. F. MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res. 1986 May;46(5):2582–2587. [PubMed] [Google Scholar]
  9. Holgate C. S., Jackson P., Cowen P. N., Bird C. C. Immunogold-silver staining: new method of immunostaining with enhanced sensitivity. J Histochem Cytochem. 1983 Jul;31(7):938–944. doi: 10.1177/31.7.6189883. [DOI] [PubMed] [Google Scholar]
  10. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  11. Maynard P. V., Blamey R. W., Elston C. W., Haybittle J. L., Griffiths K. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978 Nov;38(11 Pt 2):4292–4295. [PubMed] [Google Scholar]
  12. Price M. R., Edwards S., Robins R. A., Hilgers J., Hilkens J., Baldwin R. W. Epitopes with diagnostic and prognostic significance co-expressed on a human breast carcinoma-associated antigen. Eur J Cancer Clin Oncol. 1986 Jan;22(1):115–117. doi: 10.1016/0277-5379(86)90351-2. [DOI] [PubMed] [Google Scholar]
  13. Rasmussen B. B., Pedersen B. V., Thorpe S. M., Hilkens J., Hilgers J., Rose C. Prognostic value of surface antigens in primary human breast carcinomas, detected by monoclonal antibodies. Cancer Res. 1985 Mar;45(3):1424–1427. [PubMed] [Google Scholar]
  14. Wilkinson M. J., Howell A., Harris M., Taylor-Papadimitriou J., Swindell R., Sellwood R. A. The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer. 1984 Mar 15;33(3):299–304. doi: 10.1002/ijc.2910330304. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES